APN-1607 is a second generation [18F] Tau PET tracer currently in clinical trials that targets Tau aggregates present in several neurodegenerative diseases. Currently, APN-1607 appears to be the only PET tracer demonstrating utility in imaging both AD and non-AD tauopathies including Progressive Supranuclear Palsy (PSP), Pick’s Disease (PiD), Frontotemporal Dementia (FTD), and Corticobasal Degeneration (CBD).
Non-invasive imaging for these diseases is critical for diagnosis, tracking progression/regression and patient stratification for therapeutic trials. APN-1607 is also the first PET tracer in the landscape that can visualize Tau aggregates in animal models. This unique attribute makes it especially valuable for preclinical Tau therapeutics development, allowing molecules to be assessed in vivo before testing the molecules clinically. APRINOIA is committed to making APN-1607 widely available to speed therapeutic trials in these devastating 3R and 4R tau diseases.
Until now, APN-1607 has been used to image >100 patients world-wide. It will become an ideal diagnostic tool to forecast neurodegenerative disorders within the next 5 years.
Until end of 2018, APN-1607 has been used to image >100 patients world-wide. It will become an ideal diagnostic tool to forecast neurodegenerative disorders within the next 5 years.
APN1607 depicts the spread of tau in the AD brain
Innovative diagnostics that makes a difference in Tauopathy.
Upper Left: Normal subject. Upper Right: FTD subject.
Lower Left: PSP subject. Lower Right: CBS subject.
Tauopathies are neurodegenerative disorders caused by aggregation of Tau proteins with formations of neurofibrillary tangles. Tau aggregates are not only found in AD, but also non-AD neurodegenerative diseases, including FTD, PSP, and CBS.
APN-1607 is the first PET tracer in the landscape that can distinguish different types of AD and non-AD tauopathies, enhancing Tau-centric therapeutics more accurately.
Frontal Temporal Dementia (FTD)
Patients with Frontal Temporal Dementia (FTD) demonstrate abnormalities in frontal and temporal regions of the brain. A patient with FTD shows APN-1607 uptake in the frontotemporal regions.
It has been discovered that FTD patients demonstrate neuronal cell loss in frontal and temporal lobes and gliosis in both white and gray matter.
Progressive Supranuclear Palsy (PSP)
Progressive Supranuclear Palsy (PSP) is a movement disorder that affects patients’ rigidity. PSP is diagnosed where damage occurs in sub-cortical structures including the substantia nigra, globus pallidus, subthalamic nucleus, and the midbrain.
The application of APN-1607 indicates presence of aggregated Tau at the brainstem and subcortical regions.
Corticobasal Syndrome (CBS)
Patients with corticobasal syndrome (CBS) demonstrate abnormalities in posture and motor functions, with relatively little damage on compartments pertaining to mental activities.
Specifically, CBS patients experience atrophy in posterolateral, medial frontal cortical, and basal ganglia regions. The application of APN-1607 indicates presence of aggregated Tau at basal ganglia, thalamus, and, to a lesser extent, the brainstem.